Indomethacin in Pregnancy: Applications and Safety

Gael Abou-Ghannam; Ihab M. Usta; Anwar H. Nassar

doi:10.1055/s-0031-1284227

American Journal of Perinatology, Table of Contents

Am J Perinatol 2012; 29(03): 175-186
DOI: 10.1055/s-0031-1284227

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Indomethacin in Pregnancy: Applications and Safety

Gael Abou-Ghannam

¹Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Hamra, Beirut, Lebanon

,

Ihab M. Usta

¹Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Hamra, Beirut, Lebanon

,

Anwar H. Nassar

¹Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Hamra, Beirut, Lebanon

› Author Affiliations

Abstract

Preterm labor (PTL) is a major cause of neonatal morbidity and mortality worldwide. Among the available tocolytics, indomethacin, a prostaglandin synthetase inhibitor, has been in use since the 1970s. Recent studies have suggested that prostaglandin synthetase inhibitors are superior to other tocolytics in delaying delivery for 48 hours and 7 days. However, increased neonatal complications including oligohydramnios, renal failure, necrotizing enterocolitis, intraventricular hemorrhage, and closure of the patent ductus arteriosus have been reported with the use of indomethacin. Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios. This article describes the mechanism of action of indomethacin and its clinical applications as a tocolytic agent in women with PTL and cerclage and its use in the context of polyhydramnios. The fetal and neonatal side effects of this drug are also summarized and guidelines for its use are proposed.

Keywords

indomethacin - tocolysis - preterm labor - short cervix - polyhydramnios - fetal side effects

Full Text

References

References
1 Paneth NS. The problem of low birth weight. Future Child 1995; 5: 19-34
2 Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84
3 ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin. Management of preterm labor. Number 43, May 2003. Int J Gynaecol Obstet 2003; 82: 127-135
4 Gordon MC, Samuels P. Indomethacin. Clin Obstet Gynecol 1995; 38: 697-705
5 Hui D, Liu G, Kavuma E, Hewson SA, McKay D, Hannah ME. Preterm labour and birth: a survey of clinical practice regarding use of tocolytics, antenatal corticosteroids, and progesterone. J Obstet Gynaecol Can 2007; 29: 117-130
6 Klauser CK, Briery CM, Magann EF, Martin RW, Chauhan SP, Morrison JC. Tocolytic preference for treatment of preterm labor. J Miss State Med Assoc 2007; 48: 35-38
7 Gamissans O, Balasch J. Prostaglandin synthetase inhibitors in the treatment of preterm birth. In: Fuchs A-R, Stubblefield PG, Fuchs F, eds. Preterm Birth: Causes, Prevention, and Management. 2nd ed. New York: McGraw-Hill; 1993: 309-332
8 Niebyl JR, Blake DA, White RD , et al. The inhibition of premature labor with indomethacin. Am J Obstet Gynecol 1980; 136: 1014-1019
9 Sawdy R, Knock GA, Bennett PR, Poston L, Aaronson PI. Effect of nimesulide and indomethacin on contractility and the Ca2 + channel current in myometrial smooth muscle from pregnant women. Br J Pharmacol 1998; 125: 1212-1217
10 Allport VC, Pieber D, Slater DM, Newton R, White JO, Bennett PR. Human labour is associated with nuclear factor-kappaB activity which mediates cyclo-oxygenase-2 expression and is involved with the “functional progesterone withdrawal. ”Mol Hum Reprod 2001; 7: 581-586
11 Allport VC, Slater DM, Newton R, Bennett PR. NF-kappaB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol Hum Reprod 2000; 6: 561-565
12 Elliott CL, Allport VC, Loudon JA, Wu GD, Bennett PR. Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol Hum Reprod 2001; 7: 787-790
13 Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80
14 Loudon JA, Groom KM, Bennett PR. Prostaglandin inhibitors in preterm labour. Best Pract Res Clin Obstet Gynaecol 2003; 17: 731-744
15 O'Brien WF. The role of prostaglandins in labor and delivery. Clin Perinatol 1995; 22: 973-984
16 Bry K, Hallman M. Prostaglandins, inflammation, and preterm labor. J Perinatol 1989; 9: 60-65
17 Dong YL, Gangula PR, Fang L, Yallampalli C. Differential expression of cyclooxygenase-1 and -2 proteins in rat uterus and cervix during the estrous cycle, pregnancy, labor and in myometrial cells. Prostaglandins 1996; 52: 13-34
18 Steinborn A, Günes H, Halberstadt E. Signal for term parturition is of trophoblast and therefore of fetal origin. Prostaglandins 1995; 50: 237-252
19 Rajabi MR, Cybulsky AV. Phospholipase A2 activity is increased in guinea pig uterine cervix in late pregnancy and at parturition. Am J Physiol 1995; 269 (5 Pt 1) E940-E947
20 Teixeira FJ, Zakar T, Hirst JJ , et al. Prostaglandin endoperoxide-H synthase (PGHS) activity and immunoreactive PGHS-1 and PGHS-2 levels in human amnion throughout gestation, at term, and during labor. J Clin Endocrinol Metab 1994; 78: 1396-1402
21 Cox SM, King MR, Casey ML, MacDonald PC. Interleukin-1 beta, -1 alpha, and -6 and prostaglandins in vaginal/cervical fluids of pregnant women before and during labor. J Clin Endocrinol Metab 1993; 77: 805-815
22 Parilla BV, Tamura RK, Cohen LS, Clark E. Lack of effect of antenatal indomethacin on fetal cerebral blood flow. Am J Obstet Gynecol 1997; 176: 1166-1169, discussion 1169–1171
23 Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J Perinat Med 1984; 12: 25-29
24 Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol 1993; 169: 97-102
25 Kurki T, Eronen M, Lumme R, Ylikorkala O. A randomized double-dummy comparison between indomethacin and nylidrin in threatened preterm labor. Obstet Gynecol 1991; 78: 1093-1097
26 Stika CS, Gross GA, Leguizamon G , et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol 2002; 187: 653-660
27 Morales WJ, Smith SG, Angel JL, O'Brien WF, Knuppel RA. Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study. Obstet Gynecol 1989; 74: 567-572
28 Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Br J Obstet Gynaecol 1999; 106: 467-473
29 Besinger RE, Niebyl JR, Keyes WG, Johnson TR. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol 1991; 164: 981-986, discussion 986–988
30 Macones GA, Marder SJ, Clothier B, Stamilio DM. The controversy surrounding indomethacin for tocolysis. Am J Obstet Gynecol 2001; 184: 264-272
31 Doyle NM, Gardner MO, Wells L, Qualls C, Papile LA. Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis. J Perinatol 2005; 25: 336-340
32 Alván G, Orme M, Bertilsson L, Ekstrand R, Palmér L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther 1975; 18: 364-373
33 Bhat R, Vidyasagar D, Vadapalli M , et al. Disposition of indomethacin in preterm infants. J Pediatr 1979; 95: 313-316
34 Insel P. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996: 617-658
35 vd Heijden AJ, Provoost AP, Nauta J , et al. Renal functional impairment in preterm neonates related to intrauterine indomethacin exposure. Pediatr Res 1988; 24: 644-648
36 Van den Veyver IB, Moise Jr KJ. Prostaglandin synthetase inhibitors in pregnancy. Obstet Gynecol Surv 1993; 48: 493-502
37 Fortson W, Beharry KD, Nageotte S , et al. Vaginal versus oral indomethacin in a rabbit model for non-infection-mediated preterm birth: an alternate tocolytic approach. Am J Obstet Gynecol 2006; 195: 1058-1064
38 Abramov Y, Nadjari M, Weinstein D, Ben-Shachar I, Plotkin V, Ezra Y. Indomethacin for preterm labor: a randomized comparison of vaginal and rectal-oral routes. Obstet Gynecol 2000; 95: 482-486
39 Locatelli A, Vergani P, Bellini P, Strobelt N, Ghidini A. Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?. BJOG 2001; 108: 325-326
40 Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis D. Randomized comparative trial of indomethacin and sulindac for the treatment of refractory preterm labor. Obstet Gynecol 1992; 79: 223-228
41 King JF, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005; 2: CD001992
42 Katz Z, Lancet M, Yemini M, Mogilner BM, Feigl A, Ben Hur H. Treatment of premature labor contractions with combined ritodrine and indomethacine. Int J Gynaecol Obstet 1983; 21: 337-342
43 Bivins Jr HA, Newman RB, Fyfe DA, Campbell BA, Stramm SL. Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor. Am J Obstet Gynecol 1993; 169: 1065-1070
44 McWhorter J, Carlan SJ, OLeary TD, Richichi K, OBrien WF. Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstet Gynecol 2004; 103 (5 Pt 1) 923-930
45 Kramer WB, Saade GR, Belfort M, Dorman K, Mayes M, Moise Jr KJ. A randomized double-blind study comparing the fetal effects of sulindac to terbutaline during the management of preterm labor. Am J Obstet Gynecol 1999; 180 (2 Pt 1) 396-401
46 Schorr SJ, Ascarelli MH, Rust OA , et al. A comparative study of ketorolac (Toradol) and magnesium sulfate for arrest of preterm labor. South Med J 1998; 91: 1028-1032
47 Eronen M, Pesonen E, Kurki T, Teramo K, Ylikorkala O, Hallman M. Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor. J Pediatr 1994; 124 (5 Pt 1) 782-788
48 Gamissans O, Cañas E, Cararach V, Ribas J, Puerto B, Edo A. A study of indomethacin combined with ritodrine in threatened preterm labor. Eur J Obstet Gynecol Reprod Biol 1978; 8: 123-128
49 Spearing G. Alcohol, indomethacin, and salbutamol. A comparative trial of their use in preterm labor. Obstet Gynecol 1979; 53: 171-174
50 Newton ER, Shields L, Ridgway III LE, Berkus MD, Elliott BD. Combination antibiotics and indomethacin in idiopathic preterm labor: a randomized double-blind clinical trial. Am J Obstet Gynecol 1991; 165 (6 Pt 1) 1753-1759
51 Higby K, Xenakis EM, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol 1993; 168: 1247-1256, discussion 1256–1259
52 Vermillion ST, Landen CN. Prostaglandin inhibitors as tocolytic agents. Semin Perinatol 2001; 25: 256-262
53 Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113: 585-594
54 Tan TC, Devendra K, Tan LK, Tan HK. Tocolytic treatment for the management of preterm labour: a systematic review. Singapore Med J 2006; 47: 361-366
55 Berghella V, Iams JD, Newman RB , et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Frequency of uterine contractions in asymptomatic pregnant women with or without a short cervix on transvaginal ultrasound scan. Am J Obstet Gynecol 2004; 191: 1253-1256
56 Lewis D, Pelham JJ, Done E, Sawhney H, Talucci M, Berghella V. Uterine contractions in asymptomatic pregnant women with a short cervix on ultrasound. J Matern Fetal Neonatal Med 2005; 18: 325-328
57 Vitoratos N, Hassiakos D, Louridas C, Limuris G, Zourlas PA. Prostaglandin F1a and prostaglandin E2 plasma levels after transvaginal cervical cerclage. Clin Exp Obstet Gynecol 1996; 23: 21-25
58 Visintine J, Airoldi J, Berghella V. Indomethacin administration at the time of ultrasound-indicated cerclage: is there an association with a reduction in spontaneous preterm birth?. Am J Obstet Gynecol 2008; 198: 643, e1-e3
59 Berghella V, Prasertcharoensuk W, Cotter A , et al. Does indomethacin prevent preterm birth in women with cervical dilatation in the second trimester?. Am J Perinatol 2009; 26: 13-19
60 Berghella V, Rust OA, Althuisius SM. Short cervix on ultrasound: does indomethacin prevent preterm birth?. Am J Obstet Gynecol 2006; 195: 809-813
61 Rust OA, Atlas RO, Reed J, van Gaalen J, Balducci J. Revisiting the short cervix detected by transvaginal ultrasound in the second trimester: why cerclage therapy may not help. Am J Obstet Gynecol 2001; 185: 1098-1105
62 Althuisius SM, Dekker GA, Hummel P, Bekedam DJ, van Geijn HP. Final results of the Cervical Incompetence Prevention Randomized Cerclage Trial (CIPRACT): therapeutic cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol 2001; 185: 1106-1112
63 To MS, Alfirevic Z, Heath VC , et al; Fetal Medicine Foundation Second Trimester Screening Group. Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. Lancet 2004; 363: 1849-1853
64 Berghella V, Odibo AO, Tolosa JE. Cerclage for prevention of preterm birth in women with a short cervix found on transvaginal ultrasound examination: a randomized trial. Am J Obstet Gynecol 2004; 191: 1311-1317
65 Kofinas A, Kofinas J. Indomethacin as a diagnostic and therapeutic tool in the management of progressive cervical shortening diagnosed by trans-vaginal sonography. J Matern Fetal Neonatal Med 2011; 24: 79-85
66 Jeyabalan A, Caritis SN. Pharmacologic inhibition of preterm labor. Clin Obstet Gynecol 2002; 45: 99-113
67 Lunt CC, Satin AJ, Barth Jr WH, Hankins GD. The effect of indomethacin tocolysis on maternal coagulation status. Obstet Gynecol 1994; 84: 820-822
68 Lissak A, Fruchter OH, Abramovici H. Uncommon adverse maternal effects with indomethacin for tocolysis. Int J Gynaecol Obstet 1999; 67: 183-185
69 Mari G, Moise Jr KJ, Deter RL, Kirshon B, Carpenter RJ. Doppler assessment of the renal blood flow velocity waveform during indomethacin therapy for preterm labor and polyhydramnios. Obstet Gynecol 1990; 75: 199-201
70 Moise Jr KJ, Mari G, Kirshon B, Huhta JC, Walsh SW, Cano L. The effect of indomethacin on the pulsatility index of the umbilical artery in human fetuses. Am J Obstet Gynecol 1990; 162: 199-202
71 Klein KL, Scott WJ, Clark KE, Wilson JG. Indomethacin—placental transfer, cytotoxicity, and teratology in the rat. Am J Obstet Gynecol 1981; 141: 448-452
72 Traeger A, Nöschel H, Zaumseil J. [Pharmacokinetics of indomethacin in pregnant and parturient women and in their newborn infants]. Zentralbl Gynakol 1973; 95: 635-641
73 Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993; 329: 1602-1607
74 Merrill JD, Clyman RI, Norton ME. Indomethacin as a tocolytic agent: the controversy continues. J Pediatr 1994; 124 (5 Pt 1) 734-736
75 Marpeau L, Bouillie J, Barrat J, Milliez J. Obstetrical advantages and perinatal risks of indomethacin: a report of 818 cases. Fetal Diagn Ther 1994; 9: 110-115
76 Friedman S, Flidel-Rimon O, Steinberg M, Shinwell ES. Indomethacin tocolysis and white matter injury in preterm infants. J Matern Fetal Neonatal Med 2005; 18: 87-91
77 Baerts W, Fetter WP, Hop WC, Wallenburg HC, Spritzer R, Sauer PJ. Cerebral lesions in preterm infants after tocolytic indomethacin. Dev Med Child Neurol 1990; 32: 910-918
78 Iannucci TA, Besinger RE, Fisher SG, Gianopoulos JG, Tomich PG. Effect of dual tocolysis on the incidence of severe intraventricular hemorrhage among extremely low-birth-weight infants. Am J Obstet Gynecol 1996; 175 (4 Pt 1) 1043-1046
79 Weintraub Z, Solovechick M, Reichman B , et al; Israel Neonatal Network. Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2001; 85: F13-F17
80 Ojala R, Ikonen S, Tammela O. Perinatal indomethacin treatment and neonatal complications in preterm infants. Eur J Pediatr 2000; 159: 153-155
81 Souter D, Harding J, McCowan L, O'Donnell C, McLeay E, Baxendale H. Antenatal indomethacin—adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998; 38: 11-16
82 Gardner MO, Owen J, Skelly S, Hauth JC. Preterm delivery after indomethacin. A risk factor for neonatal complications?. J Reprod Med 1996; 41: 903-906
83 Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997; 177: 256-259, discussion 259–261
84 Suarez RD, Grobman WA, Parilla BV. Indomethacin tocolysis and intraventricular hemorrhage. Obstet Gynecol 2001; 97: 921-925
85 Ment LR, Oh W, Ehrenkranz RA , et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994; 93: 543-550
86 Ment LR, Oh W, Ehrenkranz RA , et al. Low dose indomethacin and extension of intraventricular hemorrhage. J Pediatr 1994; 124: 951-955
87 Leffler CW, Busija DW, Fletcher AM, Beasley DG, Hessler JR, Green RS. Effects of indomethacin upon cerebral hemodynamics of newborn pigs. Pediatr Res 1985; 19: 1160-1164
88 Friedman Z, Whitman V, Maisels MJ, Berman Jr W, Marks KH, Vesell ES. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol 1978; 18: 272-279
89 Vermillion ST, Newman RB. Recent indomethacin tocolysis is not associated with neonatal complications in preterm infants. Am J Obstet Gynecol 1999; 181 (5 Pt 1) 1083-1086
90 Ment LR, Duncan CC, Ehrenkranz RA , et al. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. J Pediatr 1988; 112: 948-955
91 Bandstra ES, Montalvo BM, Goldberg RN , et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics 1988; 82: 533-542
92 Yanowitz TD, Yao AC, Werner JC, Pettigrew KD, Oh W, Stonestreet BS. Effects of prophylactic low-dose indomethacin on hemodynamics in very low birth weight infants. J Pediatr 1998; 132: 28-34
93 Ment LR, Stewart WB, Ardito TA, Huang E, Madri JA. Indomethacin promotes germinal matrix microvessel maturation in the newborn beagle pup. Stroke 1992; 23: 1132-1137
94 Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol 2005; 106: 173-179
95 Amin SB, Sinkin RA, Glantz JC. Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. Am J Obstet Gynecol 2007; 197: 486, e1-e10
96 Major CA, Lewis DF, Harding JA, Porto MA, Garite TJ. Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate. Am J Obstet Gynecol 1994; 170 (1 Pt 1) 102-106
97 Restaino I, Kaplan BS, Kaplan P, Rosenberg HK, Witzleben C, Roberts N. Renal dysgenesis in a monozygotic twin: association with in utero exposure to indomethacin. Am J Med Genet 1991; 39: 252-257
98 Gloor JM, Muchant DG, Norling LL. Prenatal maternal indomethacin use resulting in prolonged neonatal renal insufficiency. J Perinatol 1993; 13: 425-427
99 Kaplan BS, Restaino I, Raval DS, Gottlieb RP, Bernstein J. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1994; 8: 700-704
100 Cantor B, Tyler T, Nelson RM, Stein GH. Oligohydramnios and transient neonatal anuria: a possible association with the maternal use of prostaglandin synthetase inhibitors. J Reprod Med 1980; 24: 220-223
101 Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989; 160: 1525-1530, discussion 1530–1531
102 Goldenberg RL, Davis RO, Baker RC. Indomethacin-induced oligohydramnios. Am J Obstet Gynecol 1989; 160 (5 Pt 1) 1196-1197
103 Hill LM, Lazebnik N, Many A. Effect of indomethacin on individual amniotic fluid indices in multiple gestations. J Ultrasound Med 1996; 15: 395-399
104 Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol 1990; 97: 312-316
105 de Wit W, van Mourik I, Wiesenhaan PF. Prolonged maternal indomethacin therapy associated with oligohydramnios. Case reports. Br J Obstet Gynaecol 1988; 95: 303-305
106 Nishikubo T, Takahashi Y, Nakagawa Y , et al. Renal impairment in very low birthweight infants following antenatal indomethacin administration. Acta Paediatr Jpn 1994; 36: 202-206
107 Itskovitz J, Abramovici H, Brandes JM. Oligohydramnion, meconium and perinatal death concurrent with indomethacin treatment in human pregnancy. J Reprod Med 1980; 24: 137-140
108 Vanhaesebrouck P, Thiery M, Leroy JG , et al. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr 1988; 113: 738-743
109 Pomeranz A, Korzets Z, Dolfin Z, Eliakim A, Bernheim J, Wolach B. Acute renal failure in the neonate induced by the administration of indomethacin as a tocolytic agent. Nephrol Dial Transplant 1996; 11: 1139-1141
110 Gleason CA, Clyman RI, Heymann MA, Mauray F, Leake R, Roman C. Indomethacin and patent ductus arteriosus: effects on renal function in preterm lambs. Am J Physiol 1988; 254 (1 Pt 2) F38-F44
111 Kirshon B, Moise Jr KJ, Mari G, Willis R. Long-term indomethacin therapy decreases fetal urine output and results in oligohydramnios. Am J Perinatol 1991; 8: 86-88
112 Sandruck JC, Grobman WA, Gerber SE. The effect of short-term indomethacin therapy on amniotic fluid volume. Am J Obstet Gynecol 2005; 192: 1443-1445
113 Sawdy RJ, Lye S, Fisk NM, Bennett PR. A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. Am J Obstet Gynecol 2003; 188: 1046-1051
114 Novy MJ. Effects of indomethacin on labor, fetal oxygenation, and fetal development in rhesus monkeys. Adv Prostaglandin Thromboxane Res 1978; 4: 285-300
115 Wurtzel D. Prenatal administration of indomethacin as a tocolytic agent: effect on neonatal renal function. Obstet Gynecol 1990; 76: 689-692
116 Savage AH, Anderson BL, Simhan HN. The safety of prolonged indomethacin therapy. Am J Perinatol 2007; 24: 207-213
117 Butler-O'Hara M, D'Angio CT. Risk of persistent renal insufficiency in premature infants following the prenatal use of indomethacin for suppression of preterm labor. J Perinatol 2002; 22: 541-546
118 Veersema D, de Jong PA, van Wijck JA. Indomethacin and the fetal renal nonfunction syndrome. Eur J Obstet Gynecol Reprod Biol 1983; 16: 113-121
119 Miall LS, Henderson MJ, Turner AJ , et al. Plasma creatinine rises dramatically in the first 48 hours of life in preterm infants. Pediatrics 1999; 104: e76
120 Eronen M, Pesonen E, Kurki T, Ylikorkala O, Hallman M. The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized double-blind study. Am J Obstet Gynecol 1991; 164 (1 Pt 1) 141-146
121 Moise Jr KJ. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993; 168: 1350-1353
122 Moise Jr KJ, Huhta JC, Sharif DS , et al. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 1988; 319: 327-331
123 Rudolph AM, Heymann MA. Hemodynamic changes induced by blockers of prostaglandin synthesis in the fetal lamb in utero. Adv Prostaglandin Thromboxane Res 1978; 4: 231-237
124 Suarez VR, Thompson LL, Jain V , et al. The effect of in utero exposure to indomethacin on the need for surgical closure of a patent ductus arteriosus in the neonate. Am J Obstet Gynecol 2002; 187: 886-888
125 Momma K, Takao A. In vivo constriction of the ductus arteriosus by nonsteroidal antiinflammatory drugs in near-term and preterm fetal rats. Pediatr Res 1987; 22: 567-572
126 Reese J, Anderson JD, Brown N, Roman C, Clyman RI. Inhibition of cyclooxygenase isoforms in late- but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1717-R1723
127 Clyman RI, Chen YQ, Chemtob S , et al. In utero remolding of the fetal lamb ductus arteriosus. Vasa vasorum proliferation, neointimal formation, and cell death. Circulation 2001; 103: 1806-1812
128 Hammerman C, Glaser J, Kaplan M, Schimmel MS, Ferber B, Eidelman AI. Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics 1998; 102: E56
129 Karunasiri M, Nasbaum H, Pinheiro J. Tocolysis with indomethacin is associated with patent ductus arteriosus refractory to therapy. [abstract]. Pediatr Res 1996; 39: 221A
130 Räsänen J, Jouppila P. Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. Am J Obstet Gynecol 1995; 173: 20-25
131 Kirshon B, Mari G, Moise Jr KJ, Wasserstrum N. Effect of indomethacin on the fetal ductus arteriosus during treatment of symptomatic polyhydramnios. J Reprod Med 1990; 35: 529-532
132 Respondek M, Weil SR, Huhta JC. Fetal echocardiography during indomethacin treatment. Ultrasound Obstet Gynecol 1995; 5: 86-89
133 Niebyl JR, Witter FR. Neonatal outcome after indomethacin treatment for preterm labor. Am J Obstet Gynecol 1986; 155: 747-749
134 Levy R, Matitiau A, Ben Arie A, Milman D, Or Y, Hagay Z. Indomethacin and corticosteroids: an additive constrictive effect on the fetal ductus arteriosus. Am J Perinatol 1999; 16: 379-383
135 Momma K, Toyoshima K, Ito K , et al. Delayed neonatal closure of the ductus arteriosus following early in utero exposure to indomethacin in the rat. Neonatology 2009; 96: 69-79
136 Neu J, Wu-Wang CY. Eicosanoids in the developing gastrointestinal tract. Semin Perinatol 1987; 11: 22-30
137 Wallace JL, Cohen MM. Gastric mucosal protection with chronic mild restraint: role of endogenous prostaglandins. Am J Physiol 1984; 247 (2 Pt 1) G127-G132
138 Peskar BM. On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs. Biochim Biophys Acta 1977; 487: 307-314
139 Meyers RL, Alpan G, Lin E, Clyman RI. Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res 1991; 29: 569-574
140 Parilla BV, Grobman WA, Holtzman RB, Thomas HA, Dooley SL. Indomethacin tocolysis and risk of necrotizing enterocolitis. Obstet Gynecol 2000; 96: 120-123
141 Ramsey P, Ramin K, Derleth D , et al. Indomethacin tocolysis is not associated with an increased incidence of isolated bowel perforations in premature neonates. [abstract]. Am J Obstet Gynecol 1997; 176: S45
142 Abbasi S, Gerdes JS, Sehdev HM, Samimi SS, Ludmir J. Neonatal outcome after exposure to indomethacin in utero: a retrospective case cohort study. Am J Obstet Gynecol 2003; 189: 782-785
143 Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol 2005; 106: 173-179
144 Bustos R, Ballejo G, Giussi G, Rosas R, Isa JC. Inhibition of fetal lung maturation by indomethacin in pregnant rabbits. J Perinat Med 1978; 6: 240-245
145 Macones GA, Robinson CA. Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am J Obstet Gynecol 1997; 177: 819-824
146 Moise Jr KJ. Indomethacin therapy in the treatment of symptomatic polyhydramnios. Clin Obstet Gynecol 1991; 34: 310-318
147 Cabrol D, Landesman R, Muller J, Uzan M, Sureau C, Saxena BB. Treatment of polyhydramnios with prostaglandin synthetase inhibitor (indomethacin). Am J Obstet Gynecol 1987; 157: 422-426
148 Mamopoulos M, Assimakopoulos E, Reece EA, Andreou A, Zheng XZ, Mantalenakis S. Maternal indomethacin therapy in the treatment of polyhydramnios. Am J Obstet Gynecol 1990; 162: 1225-1229
149 Kirshon B, Mari G, Moise Jr KJ. Indomethacin therapy in the treatment of symptomatic polyhydramnios. Obstet Gynecol 1990; 75: 202-205
150 Lange IR, Harman CR, Ash KM, Manning FA, Menticoglou S. Twin with hydramnios: treating premature labor at source. Am J Obstet Gynecol 1989; 160: 552-557
151 Gerson A, Roberts N, Colmorgen G, Maynard C, Slate W, Smith K. Treatment of polyhydramnios with indomethacin. Am J Perinatol 1991; 8: 97-98
152 Rosen DJ, Rabinowitz R, Beyth Y, Fejgin MD, Nicolaides KH. Fetal urine production in normal twins and in twins with acute polyhydramnios. Fetal Diagn Ther 1990; 5: 57-60
153 Ash K, Harman CR, Gritter H. TRAP sequence—successful outcome with indomethacin treatment. Obstet Gynecol 1990; 76 (5 Pt 2) 960-962
154 Malas HZ, Hamlett JD. Acute recurrent polyhydramnios—management with indomethacin. Br J Obstet Gynaecol 1991; 98: 583-587
155 Restaino I, Kaplan BS, Kaplan P, Rosenberg HK, Witzleben C, Roberts N. Renal dysgenesis in a monozygotic twin: association with in utero exposure to indomethacin. Am J Med Genet 1991; 39: 252-257
156 Faber BL. [Recurrent acute polyhydramnios treated with indomethacin]. S Afr Med J 1990; 78: 215-216
157 Nordström L, Westgren M. Indomethacin treatment for polyhydramnios. Effective but potentially dangerous?. Acta Obstet Gynecol Scand 1992; 71: 239-241
158 Mohen D, Newnham JP, D'Orsogna L. Indomethacin for the treatment of polyhydramnios: a case of constriction of the ductus arteriosus. Aust N Z J Obstet Gynaecol 1992; 32: 243-246
159 Dolkart LA, Eshwar KP, Reimers FT. Indomethacin therapy and chronic hemodialysis during pregnancy. A case report. J Reprod Med 1992; 37: 181-183
160 Deeny M, Haxton MJ. Indomethacin use to control gross polyhydramnios complicating triplet pregnancy. Br J Obstet Gynaecol 1993; 100: 281-282
161 Carmona F, Martínez-Román S, Mortera C, Puerto B, Cararach V, Iglesias X. Efficacy and safety of indomethacin therapy for polyhydramnios. Eur J Obstet Gynecol Reprod Biol 1993; 52: 175-180
162 Moise Jr KJ. Polyhydramnios. Clin Obstet Gynecol 1997; 40: 266-279
163 Abhyankar S, Salvi VS. Indomethacin therapy in hydramnios. J Postgrad Med 2000; 46: 176-178
164 Kramer WB, Van den Veyver IB, Kirshon B. Treatment of polyhydramnios with indomethacin. Clin Perinatol 1994; 21: 615-630
165 Vigil-de Gracia PE, Campos-Rivera P, Lasso-de la Vega J. [Pregnancy complicated with symptomatic polyhydramnios: treatment with indomethacin]. Ginecol Obstet Mex 1997; 65: 21-26
166 Cabrol D, Jannet D, Pannier E. Treatment of symptomatic polyhydramnios with indomethacin. Eur J Obstet Gynecol Reprod Biol 1996; 66: 11-15
167 Kriplani A, Abbi M, Banerjee N, Roy KK, Takkar D. Indomethacin therapy in the treatment of polyhydramnios due to placental chorioangioma. J Obstet Gynaecol Res 2001; 27: 245-248
168 Bondagji N, Manning FA, Martel J, Harman CR, Morrison I. Complete resolution of CMV-associated acute hydramnios by single large volume reduction amniocentesis and maternal indomethacin. A case report. Fetal Diagn Ther 1996; 11: 345-347